Dickler MN, Tolaney SM, Rugo HS, et al.: MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2- Metastatic Breast Cancer.
Clin Cancer Res 23 (17): 5218-5224, 2017.[PUBMED Abstract] Baselga J, Campone M, Piccart M, et al.: Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.
N Engl J Med 366 (6): 520-9, 2012.[PUBMED Abstract] Piccart M, Hortobagyi GN, Campone M, et al.: Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2â€ .